<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596150</url>
  </required_header>
  <id_info>
    <org_study_id>CTMX-2009-002</org_study_id>
    <secondary_id>2020-004618-36</secondary_id>
    <nct_id>NCT04596150</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer</brief_title>
  <official_title>A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination With CX-072 in Advanced Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytomX Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytomX Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, clinical study in advanced, metastatic breast cancer that will evaluate CX-2009&#xD;
      monotherapy in both Hormone Receptor(HR) positive/HER2 negative breast cancer and in TNBC,&#xD;
      and evaluate CX-2009+CX-072 in TNBC&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be enrolled to the treatment arm based on breast cancer subtype.&#xD;
&#xD;
      Patients will receive study treatment on Day 1 of a Q3W cycle. Treatment with CX-2009&#xD;
      monotherapy (Arms A and B) or CX-2009 in combination with CX-072 (Arm C) will be given until&#xD;
      disease progression or symptomatic deterioration, unacceptable toxicity necessitating&#xD;
      treatment discontinuation, or if the patient meets certain study defined criteria for&#xD;
      discontinuation. On-treatment tumor assessments, will occur every 6 weeks per RECIST v1.1 for&#xD;
      the first 48 weeks, and every 12 weeks thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">March 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>30 months</time_frame>
    <description>ORR is the proportion of patients in the efficacy-evaluable population with a best response of Complete Response (CR) or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Central Radiology Review (CRR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed Progression-Free Survival (PFS)</measure>
    <time_frame>30 Months</time_frame>
    <description>The time from the date of the first dose of study treatment until documentation of objective tumor progression based on RECIST v1.1 or until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>30 Months</time_frame>
    <description>The time that measurement criteria are met for CR or PR (based on RECIST v1.1) until the date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since treatment started)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>30 Months</time_frame>
    <description>The time from treatment initiation until death as a result of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) at 16 Weeks</measure>
    <time_frame>30 Months</time_frame>
    <description>This will include sum of confirmed Complete plus Partial Responses plus stable disease at 16 weeks on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) at 24 Weeks</measure>
    <time_frame>30 Months</time_frame>
    <description>This will include sum of confirmed Complete plus Partial Responses plus stable disease at 24 weeks on treatment</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Neoplasms</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Neoplasms, Triple-Negative</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms, Hormone Receptor Positive/HER2 Negative</condition>
  <arm_group>
    <arm_group_label>ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-2009 Monotherapy in advanced, metastatic Hormone Receptor (HR)-positive / Human Epidermal growth factor Receptor 2 (HER2)-negative breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B - CX-2009 Monotherapy, TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-2009 Monotherapy in advanced, metastatic Triple-Negative Breast Cancer (TNBC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C - CX-2009 Combination therapy, TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CX-2009 and CX-072 Combination therapy in advanced, metastatic TNBC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-2009</intervention_name>
    <description>Intravenous administration of the CX-2009 of 7 mg/kg administered every 3 weeks (Q3W)</description>
    <arm_group_label>ARM A - CX-2009 Monotherapy, HR-positive/HER2-negative</arm_group_label>
    <arm_group_label>ARM B - CX-2009 Monotherapy, TNBC</arm_group_label>
    <arm_group_label>ARM C - CX-2009 Combination therapy, TNBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CX-072</intervention_name>
    <description>Intravenous administration of the CX-072 of 1200 mg administered every 3 weeks (Q3W)</description>
    <arm_group_label>ARM C - CX-2009 Combination therapy, TNBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Arm A: inoperable, locally advanced or metastatic HR-positive/HER2-negative breast&#xD;
             cancer. Patients must have received 0 to 2 prior cytotoxic chemotherapy in the&#xD;
             inoperable, locally advanced, or metastatic setting&#xD;
&#xD;
          -  Arm B and Arm C: inoperable, locally advanced or metastatic TNBC; archival or fresh&#xD;
             tumor tissue must have high CD166 expression by immunohistochemistry (IHC). Patients&#xD;
             must have received 1 - 3 prior lines of therapy for inoperable, locally advanced, or&#xD;
             metastatic TNBC&#xD;
&#xD;
          -  Arm C only: Patients must be Programmed Death Ligand 1 (PD-L1) positive by an&#xD;
             FDA-approved test. For patients who have received prior checkpoint inhibitors (CPI)&#xD;
             therapy: if the CPI was the most recent treatment given prior to enrollment into this&#xD;
             study, the patient must not have progressed within 120 days of the first dose of the&#xD;
             CPI&#xD;
&#xD;
          -  Measurable disease per RECIST v1.1&#xD;
&#xD;
          -  Adults, at least 18 years of age&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status of 0 or 1&#xD;
&#xD;
          -  Adequate baseline Laboratory Values&#xD;
&#xD;
          -  Patients of childbearing potential or those with partners of childbearing potential&#xD;
             must agree to use a highly effective method of birth control at least 1 month prior to&#xD;
             first dose, during study treatment, and for a period of 50 days after the last dose of&#xD;
             CX-2009 and 105 days after the last dose of CX-072 (Arm C).&#xD;
&#xD;
          -  Patients with brain metastases that are ≤ 1 cm, are asymptomatic, and require&#xD;
             treatment may be eligible after discussion with Medical Monitor.&#xD;
&#xD;
          -  Additional inclusion criteria may apply&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  History of malignancy that was active within the previous 2 years. Exceptions include&#xD;
             localized cancers that are not related to the current cancer being treated, that are&#xD;
             considered to have been cured, and in the opinion of the Investigator present a low&#xD;
             risk for recurrence&#xD;
&#xD;
          -  Untreated symptomatic brain and/or leptomeningeal metastases&#xD;
&#xD;
          -  Unresolved prior therapy-related acute toxicity Grade &gt; 1, including neuropathy.&#xD;
             Alopecia and other nonacute toxicities are not exclusionary&#xD;
&#xD;
          -  Active or chronic corneal disorder&#xD;
&#xD;
          -  Serious concurrent illness&#xD;
&#xD;
          -  History of allogeneic tissue/solid organ transplant, stem cell transplant, or bone&#xD;
             marrow transplant&#xD;
&#xD;
          -  Arm C only:&#xD;
&#xD;
               -  History of or current active autoimmune diseases&#xD;
&#xD;
               -  History of myocarditis regardless of the cause&#xD;
&#xD;
               -  History of intolerance to prior immune CPI therapy defined as the need to&#xD;
                  discontinue treatment due to an immune-related Adverse Event (AE)&#xD;
&#xD;
               -  Immunosuppressive therapy including chronic systemic steroid (≥ 10 mg daily&#xD;
                  prednisone equivalents) within 14 days of Cycle 1 Day 1 (C1D1). However, patients&#xD;
                  who require brief courses of steroids (eg, as prophylaxis for IV contrast or for&#xD;
                  treatment of an allergic reaction) may be eligible with Medical Monitor approval.&#xD;
                  Inhaled or topical steroids are permitted.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to previous monoclonal antibody&#xD;
             (mAb) therapy or known hypersensitivity to any component of Probody therapeutic&#xD;
&#xD;
          -  Prior treatment with maytansinoid-containing drug conjugates (eg, DM1 or DM4 antibody&#xD;
             drug conjugate, including trastuzumab emtansine)&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Additional exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia E. Paton, Pharm D</last_name>
    <role>Study Director</role>
    <affiliation>CytomX Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darrin Bomba</last_name>
    <phone>(650) 515-3185</phone>
    <email>clinicaltrials@cytomx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fred Kerwood</last_name>
    <phone>(650) 515-3185</phone>
    <email>clinicaltrials@cytomx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles Hematology Oncology Medical</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USC Norris Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CPMC</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA David Geffen</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FCS - South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Assoc of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FCS - North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DRCI</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Allina Health System</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MUSC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Health East Texas HOPE Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kadlec Clinic Hematology and Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Summit Cancer Centers</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Cheonan Hospital SCHMC</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramn y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal, HM CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR-positive/HER2-non-amplified</keyword>
  <keyword>HR+</keyword>
  <keyword>HER2 non-amplified</keyword>
  <keyword>Hormone Receptor</keyword>
  <keyword>N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4)</keyword>
  <keyword>Cluster of Differentiation 166 (CD166)</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Probody</keyword>
  <keyword>Armed antibody</keyword>
  <keyword>Mytansine</keyword>
  <keyword>Hormone Receptor Positive</keyword>
  <keyword>DM4</keyword>
  <keyword>CD166</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

